Enovis (NYSE:ENOV) PT Lowered to $62.00 at Evercore ISI

Enovis (NYSE:ENOV) had its price target decreased by Evercore ISI from $70.00 to $62.00 in a research report sent to investors on Tuesday, Benzinga reports. Evercore ISI currently has an outperform rating on the stock.

Several other analysts have also issued reports on the stock. Needham & Company LLC restated a buy rating and set a $82.00 target price on shares of Enovis in a research report on Friday, May 3rd. JPMorgan Chase & Co. started coverage on shares of Enovis in a research note on Thursday, June 13th. They set a neutral rating and a $53.00 price target on the stock. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus price target of $71.44.

Enovis Price Performance

NYSE ENOV opened at $44.44 on Tuesday. The stock has a market capitalization of $2.44 billion, a price-to-earnings ratio of -29.63 and a beta of 1.92. Enovis has a 1-year low of $43.04 and a 1-year high of $66.14. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.10 and a quick ratio of 1.03. The business’s fifty day moving average price is $48.71 and its 200-day moving average price is $55.48.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $0.50 EPS for the quarter, meeting analysts’ consensus estimates of $0.50. The company had revenue of $516.00 million during the quarter, compared to analysts’ expectations of $505.62 million. Enovis had a positive return on equity of 3.98% and a negative net margin of 4.51%. Enovis’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.44 earnings per share. On average, equities analysts predict that Enovis will post 2.62 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Envestnet Asset Management Inc. lifted its position in shares of Enovis by 134.1% in the third quarter. Envestnet Asset Management Inc. now owns 128,259 shares of the company’s stock valued at $6,763,000 after acquiring an additional 73,461 shares in the last quarter. Northern Trust Corp lifted its holdings in Enovis by 8.5% in the 3rd quarter. Northern Trust Corp now owns 435,926 shares of the company’s stock worth $22,986,000 after purchasing an additional 34,142 shares in the last quarter. Natixis Advisors L.P. bought a new position in Enovis in the 3rd quarter worth approximately $622,000. Trexquant Investment LP purchased a new stake in Enovis during the 3rd quarter valued at approximately $599,000. Finally, Tower Research Capital LLC TRC raised its position in shares of Enovis by 17.8% during the third quarter. Tower Research Capital LLC TRC now owns 6,861 shares of the company’s stock valued at $362,000 after buying an additional 1,037 shares during the last quarter. Institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.